Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Mallinckrodt
Colorcon
Merck
McKesson

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Cheplapharm Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for CHEPLAPHARM, and what generic and branded alternatives to CHEPLAPHARM drugs are available?

CHEPLAPHARM has five approved drugs.



Summary for Cheplapharm
US Patents:0
Tradenames:5
Ingredients:5
NDAs:5

Drugs and US Patents for Cheplapharm

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cheplapharm XENICAL orlistat CAPSULE;ORAL 020766-001 Apr 23, 1999 RX Yes Yes   Start Trial   Start Trial
Cheplapharm CYTOVENE ganciclovir sodium INJECTABLE;INJECTION 019661-001 Jun 23, 1989 AP RX Yes Yes   Start Trial   Start Trial
Cheplapharm VESANOID tretinoin CAPSULE;ORAL 020438-001 Nov 22, 1995 DISCN Yes No   Start Trial   Start Trial
Cheplapharm GANITE gallium nitrate INJECTABLE;INJECTION 019961-002 Jan 17, 1991 DISCN No No   Start Trial   Start Trial
Cheplapharm ETOPOPHOS PRESERVATIVE FREE etoposide phosphate INJECTABLE;INJECTION 020457-001 May 17, 1996 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Cheplapharm

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cheplapharm XENICAL orlistat CAPSULE;ORAL 020766-001 Apr 23, 1999 4,598,089*PED   Start Trial
Cheplapharm CYTOVENE ganciclovir sodium INJECTABLE;INJECTION 019661-001 Jun 23, 1989 4,507,305   Start Trial
Cheplapharm ETOPOPHOS PRESERVATIVE FREE etoposide phosphate INJECTABLE;INJECTION 020457-001 May 17, 1996 RE35524   Start Trial
Cheplapharm CYTOVENE ganciclovir sodium INJECTABLE;INJECTION 019661-001 Jun 23, 1989 4,423,050   Start Trial
Cheplapharm ETOPOPHOS PRESERVATIVE FREE etoposide phosphate INJECTABLE;INJECTION 020457-001 May 17, 1996 5,041,424   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
McKinsey
Medtronic
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.